Current status and prospect of CAR-T cell immunotherapy for colorectal cancer
10.16139/j.1007-9610.2023.05.15
- VernacularTitle:CAR-T细胞免疫治疗结肠直肠癌的研究现状与展望
- Author:
Tianshuai ZHANG
1
;
Leqi ZHOU
;
Guanyu YU
;
Wei ZHANG
Author Information
1. 海军军医大学长海医院肛肠外科,上海 200433
- Keywords:
Chimeric antigen receptor T cell;
Colorectal cancer;
Immunotherapy
- From:
Journal of Surgery Concepts & Practice
2023;28(5):483-487
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor T(CAR-T)cell therapy is a new method of immunotherapy for cancer that has achieved remarkable results in treating blood tumors.However,colorectal cancer(CRC),as a solid tumor,has different characteristics from hematological tumors,which impose certain constraints on the selection of its therapeutic targets and the effectiveness of treatment of CAR-T therapy.Therefore,it is necessary to select therapeutic targets with high specificity and effectiveness according to the characteristics of CRC,as well as to break through the constraints such as adverse effects caused by the treatment and the solid tumor microenvironment,to make CAR-T therapy applicable in the treatment of CRC.This article aimed to summarize the strategy of selecting therapeutic targets for CAR-T cell immunotherapy for CRC,analyze the restrictive factors of this therapy in the treatment of CRC,and forecast the prospect of CAR-T cell immunotherapy for CRC.
